Commenced in January 2007
Paper Count: 31819
Potential cIBR-Conjugated PLGA Nanoparticles for Selective Targeting to Leukemic Cells
Abstract:The expression of LFA-1 diverges from the physiological condition, thus active targeting carrier can provide the benefits from difference into LFA-1 expression in various conditions. Here, the selectivity of cIBR-conjugated nanoparticles (cIBR-NPs), in terms of uptake, was investigated using PBMCs, Mixed PBMCMolt- 3 cells and Molt-3 cells. The expressions of LFA-1 on Molt-3 cells, from flow cytometry and Western blot, possessed the highest level whereas PBMCs showed the lowest level. The kinetic uptake profiles of cIBR-NPs were obtained by flow cytometry, which the degree of cellular uptake presented a similar trend with the level of LFA-1 indicating the influence of LFA-1 expression on the cellular uptake of cIBR-NPs. The conformation of LFA-1 had a slight effect on the cellular uptake of cIBR-NPs. Overall we demonstrated that cIBR-NPs enhanced cellular uptake and improved the selectivity of drug carriers to LFA-1 on the leukemia cells, which related with the order of LFA-1 expression.
Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1062198Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1675
 Hino M, et al. Leptin Receptor and Leukemia. Leukemia Lymphoma 2000; 36(5-6):457-461.
 Stirewalt DL & Radich JP The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 2003; 3(9):650-665.
 DiJoseph J, Dougher M, Armellino D, Evans D, & Damle N Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007; 21(11):2240-2245
 B├ñchli EB, Schaer DJ, Walter RB, Fehr J, and Schoedon G. Functional expression of the CD163 scavenger receptor on acute myeloid leukemia cells of monocytic lineage. J Leukocyte Bio 2006; 79(2):312-318.
 Rock KL, Benacerraf B, and Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med 1984; 160(4):1102.
 Horst E, et al. Expression of the leucocyte integrin LFA-1 (CD11a/CD18) and its ligand ICAM-1 (CD54) in lymphoid malignancies is related to lineage derivation and stage of differentiation but not to tumor grade. Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, UK 1991; 5(10):848.
 Medeiros LJ, et al. Expression of LFA-1 in non-hodgkin's lymphoma. Cancer 1989; 63(2):255-259
 Phongpradist R, et al. LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery. Curr Pharm Design 2010; 16(21):2321-2330
 Woessner S, et al. Expression of lymphocyte function-associated antigen (LFA)-1 in B-cell chronic lymphocytic leukemia. Leukemia Lymphoma 1994; 13(5):457-461
 Chittasupho C, Manikwar P, Krise J, Siahaan T, and Berkland C. cIBR Effectively Targets Nanoparticles to LFA-1 on Acute Lymphoblastic T Cells. Mol Pharm 2009; 7(1):146-55
 Wacholtz MC, Patel S, and Lipsky P. Leukocyte function-associated antigen 1 is an activation molecule for human T cells. J Exp Med 1989; 170(2):431.
 T. Hilden, Affinity and Avidity of the LFA-1 Integrin is Regulated by Phosphorylation, Faculty of Bioscience, University of Helsinki, 2005, pp. 9-24
 Springer TA, Dustin ML, Kishimoto TK, and Marlin SD. The lymphocyte function associated LFA-1, CD2, and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5(1):223-252.
 Miller BA, Antognetti G, and Springer T. Identification of cell surface antigens present on murine hematopoietic stem cells. J Immunol 1985; 134(5):3286.
 Chigaev A, et al. Real-time Analysis of the Inside-out Regulation of Lymphocyte Function-associated Antigen-1 Revealed Similarities to and Differences from Very Late Antigen-4. J Biol Chem 2011; 286(23):20375
 Anderson M, Yakovleva T, Hu Y, and Siahaan TJ. Inhibition of ICAM- 1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett 2004; 14(6):1399- 1402
 Zimmerman T, et al. ICAM-1 Peptide Inhibitors of T-cell Adhesion bind to the allosteric site of LFA-1. An NMR Characterization. Chem Biol Drug Des 2007;70(4):347
 Chittasupho C, Shannon L, Siahaan TJ, Vines CM, & Berkland C. Nanoparticles Targeting Dendritic Cell Surface Molecules Effectively Block T Cell Conjugation and Shift Response. ACS Nano 2011; 5(3):1693-1702
 Chittasupho C, et al. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. Eur J Pharm Sci 2009; 37(2):141- 150
 Mukerjee A and Viswanatha J. Formulation, Characterization and Evaluation of Curcumin-loaded PLGA Nanospheres for Cancer Therapy. Anticancer res 2009; 29(10):3867
 Carre o R, et al. A Mechanism for Antibody-mediated Outside-in Activation of LFA-1. J Biol Chem 2008; 283(16):10642
 Lub M, van Kooyk Y, & Figdor C. Ins and outs of LFA-1. Immunol today 1 1995; 6(10):479-483
 Anderson M, Tejo B, Yakovleva T, and Siahaan TJ. Characterization of binding properties of ICAM-1 peptides to LFA-1: inhibitors of T-cell adhesion. Chem Biol Drug Des 2006; 68(1):20
 G├╝rsoy R, Jois D, and Siahaan TJ. Structural recognition of an ICAM-1 peptide by its receptor on the surface of T cells: conformational studies of cyclo (1, 12)-Pen-Pro-Arg-Gly-Gly-Ser-Val-Leu-Val-Thr-Gly-Cys- OH. J Pept Res 1999; 53(4):422-431
 Anderson ME, Yakovleva T, Hu Y, and Siahaan TJ. Inhibition of ICAM-1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett 2004; 14(6):1399-1402.
 Kim M, Carman CV, Yang W, Salas A, and Springer TA. The primacy of affinity over clustering in regulation of adhesiveness of the integrin ╬▒Lβ2. J Cell Biol 2004;167(6):1241-1253
 Anderson ME, Yakovleva T, Hu Y, Siahaan TJ. Inhibition of ICAM- 1/LFA-1-mediated heterotypic T-cell adhesion to epithelial cells: design of ICAM-1 cyclic peptides. Bioorg Med Chem Lett 2004;14(6):1399-402
 Kim M, Carman CV, Yang W, Salas A, Springer TA. The primacy of affinity over clustering in regulation of adhesiveness of the integrin ╬▒Lβ2. J Cell Biol 2004; 167(6):1241-53.